MS can follow very different patterns of evolution and variable rates of disability accumulation. Thus, many scientists and practitioners believe that new biomarkers should be sought to aid in prognosis or to augment existing means of patient stratification (Barten et al, 2010, van der Walt et al., 2010).

The gMS^®Pro EDSS Test is a breakthrough tool to identify Clinically Isolated Syndrome (CIS) patients suggestive of MS and relapsing form of MS patients at risk for rapid disease progression. Using this blood test enables physicians to predict patients at risk for rapid Expanded Disability Status Scale (EDSS) progression and therefore justifiably escalate for more aggressive therapy associated with severe side effects, therefore, avoiding disease progression and accumulation of irreversible disability and lost of Quality Of Life.

The gMS^®Pro EDSS Test measures the level of IgM antibodies to a panel of glycan structures including GAGA2, 3, 4, 6. Several studies over 462 CIS and MS patients show that the level of antibodies to a panel of GAGA molecules under the classification rule called gMS-Classifier1, identifies MS patients at risk for rapid confirmed (irreversible) EDSS progression. Hazard ratio of 2.05 for CIS patients suggestive of MS and 10.5 for relapsing form of MS. Data on file at Glycominds Laboratory, CA License Number: CLF00340032. CLIA License Number 05D2010838

The gMS^®Pro EDSS Test is performed exclusively by Glycominds Laboratory Services at our CLIA approved laboratory in Simi Valley, California (CA License Number: CLF00340032). There are currently no approved billing codes for this test which is why it is billed using the CPT Code 84999. As the only provider of this test, we ask that you adjudicate our claims based on the patients in network rates, as there is no option for the patient to use a network provider.